PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Vesting, A.J.* ; Jais, A. ; Klemm, P.* ; Steuernagel, L.* ; Wienand, P.* ; Fog-Tonnesen, M.* ; Hvid, H.* ; Schumacher, A.L.* ; Kukat, C.* ; Nolte, H.* ; Georgomanolis, T.* ; Altmüller, J.* ; Pasparakis, M.* ; Schmidt, A.* ; Krüger, M.* ; Supprian, M.S.* ; Waisman, A.* ; Straub, B.K.* ; Raschzok, N.* ; Bernier, M.* ; Birkenfeld, A.L. ; Hövelmeyer, N.* ; Brüning, J.C.* ; Wunderlich, F.T.*

NIK/MAP3K14 in hepatocytes orchestrates NASH to hepatocellular carcinoma progression via JAK2/STAT5 inhibition.

Mol. Metab. 66:101626 (2022)
Postprint Forschungsdaten DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
OBJECTIVE: Nonalcoholic fatty liver disease (NAFLD) ranges from steatosis to nonalcoholic steatohepatitis (NASH), which often progresses to hepatocellular carcinoma (HCC) through a largely undefined mechanism. NASH and HCC depend on inflammatory signaling, whose master regulator is the NFκB transcription factor family, activated by canonical and non-canonical pathways. METHODS: Here, we investigated non-canonical NFκB-inducing kinase (NIK/MAP3K14) in metabolic NASH, NASH to HCC transition, and DEN-induced HCC. To this end, we performed dietary and chemical interventions in mice that were analyzed via single nucleus sequencing, gene expression and histochemical methods. Ultimately, we verified our mouse results in human patient samples. RESULTS: We revealed that hepatocyte-specific NIK deficiency (NIKLKO) ameliorated metabolic NASH complications and reduced hepatocarcinogenesis, independent of its role in the NFκB pathway. Instead, hepatic NIK attenuated hepatoprotective JAK2/STAT5 signaling that is a prerequisite for NASH and NASH to HCC progression in mice and humans. CONCLUSIONS: Our data suggest NIK-mediated inhibitory JAK2 phosphorylation at serine 633 that might be amenable for future therapeutic interventions in patients.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Altmetric
8.568
0.000
1
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Nik In Nash To Hcc Progression ; Nik-mediated Jak2 Inhibition Impairs Stat5 Signaling; Nf-kappa-b; Hepatic Growth-hormone; Fatty Liver-disease; Tyrosine Kinase Jak2; Signal Transducer; Nonalcoholic Steatohepatitis; Protein-kinase; Phosphorylation; Activation; Expression
Sprache englisch
Veröffentlichungsjahr 2022
HGF-Berichtsjahr 2022
ISSN (print) / ISBN 2212-8778
e-ISSN 2212-8778
Zeitschrift Molecular Metabolism
Quellenangaben Band: 66, Heft: , Seiten: , Artikelnummer: 101626 Supplement: ,
Verlag Elsevier
Verlagsort Amsterdam
Begutachtungsstatus Peer reviewed
Institut(e) Helmholtz Institute for Metabolism, Obesity and Vascular Research (HI-MAG)
Institute of Diabetes Research and Metabolic Diseases (IDM)
POF Topic(s) 30201 - Metabolic Health
90000 - German Center for Diabetes Research
Forschungsfeld(er) Helmholtz Diabetes Center
PSP-Element(e) G-555600-001
G-502400-001
Förderungen Universität zu Köln
Novo Nordisk
National Institute on Aging
National Institutes of Health
CECAD
DOI 10.1016/j.molmet.2022.101626
WOS ID 000905344500005
WOS ID WOS:000905344500005
Scopus ID 85141988963
PubMed ID 36356831
Erfassungsdatum 2022-12-06
[➜Korrektur melden]